Ss-blockers in the treatment of hypertension in black patients at Herk Mmliche agents in this class, such as atenolol and bisprolol.8 is based, 9-blocker nebivolol is selective for adrenergic receptors and YEARS NO-mediated vasodilator properties.10 engined His was used by the U.S. Food and Drug Administration to treat mild to moderate hypertension. The recommended starting dose amounts to Gt 5 mg / d, which can be obtained Ht be, based on the patient’s response, and 40 mg / d, the recommended dose in patients with severe renal insufficiency mg/d.10 2.5, 11 Three 12-w chige Phase III randomized, double-blind, controlled Placebo-strips that were used by the FDA as an antihypertensive agent nebivolol, two were in populations with high total-out, and a sign in itself blacks.14 12.13 identifies the purpose of this analysis was to support joint st Rkere effectiveness and reps possibility of nebivolol, as in the general Bev lkerung with hypertension and the subpopulation of patients with black skin. Selection of research methods and data collection, each author has had in at least one of three randomized clinical trials with nebivolol or rstudien authored12 coauthored13, 14 reports of this primary. This involved three studies were from Hnlichem design to another. To make further studies to be included in this report, k Nnten identify, for other multicenter PubMed was searched, randomized, controlled trials Placebo-nebivolol Benazepril Lotensin monotherapy in stage I and II hypertension at least 12 weeks duration.
The initial research that included the words as a single agent, treatment, high blood pressure and clinical trials, nebivolol resulted in 76 publications. Of these, 40 excluded based on title alone. Summaries of the 36 other publications were evaluated, and were after excluding studies that did not include placebo arms too short, the results assessed differently than the blood pressure or the effects of nebivolol on the therapy with background other agents and / or included patients with heart failure and / or diabetes, a study15 it was found that there were to be included in the pooled analysis. This study, however, included a small sample size and was results.15 Like in the 3 studies already contain observed, 12 14, it was decided that it could not be ruled out, without adding significant bias for results. All data in this paper were ffentlichung from the third 3 of the con bundled U-phase, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies compared POSE: 202.14 ONE ONE MD and MD 302.13 305.12 ONE In tests of the ONE 302 and 305, the first visit of patients beginning and end of the last patient was in September 2001 and M March 2003, both in the trial of the ONE 202, these dates in November 2001 and in 2003 T Ao. Tests NEB MD 202 and MD 302 NEB were performed in the United States, the study of the ONE 305 Britain in the USA, grandmother, Belgium and the Netherlands was performed. Participants and study design details of the tests were already VER Published. 14th December In short, the participants were M Men and women of all races who was diagnosed with hypertension stage I-II at the time of randomization. Patients were excluded if they have a body mass index 35 kg/m2 or 40, had secondar.